These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36661718)

  • 1. Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More.
    Pécsi B; Mangel L
    Curr Oncol; 2023 Jan; 30(1):908-922. PubMed ID: 36661718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer.
    Zainal Abidin MN; Omar MS; Islahudin F; Mohamed Shah N
    BMC Cancer; 2022 Jul; 22(1):731. PubMed ID: 35787795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Real-Life Impact of mFOLFIRI-Based Chemotherapies on Elderly Patients-Should We Let It or Leave It?
    Pécsi B; Mangel LC
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
    Ciardiello D; Chiarazzo C; Famiglietti V; Damato A; Pinto C; Zampino MG; Castellano G; Gervaso L; Zaniboni A; Oneda E; Rapisardi S; Bordonaro R; Zichi C; De Vita F; Di Maio M; Parisi A; Giampieri R; Berardi R; Lavacchi D; Antonuzzo L; Tamburini E; Maiorano BA; Parrella P; Latiano TP; Normanno N; De Stefano A; Avallone A; Martini G; Napolitano S; Troiani T; Martinelli E; Ciardiello F; De Vita F; Maiello E
    ESMO Open; 2022 Oct; 7(5):100567. PubMed ID: 35994791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.
    Takahashi S; Ouchi K; Sakamoto Y; Mori T; Shimodaira H; Takahashi M; Ohori H; Kudo C; Takahashi Y; Imai H; Akiyama S; Takahashi M; Suto T; Murakawa Y; Oishi T; Isobe H; Okada Y; Kawai S; Yoshioka T; Sato T; Shindo Y; Sugiyama S; Komine K; Chiba N; Okita A; Yamaguchi T; Ishioka C
    J Gastrointest Oncol; 2023 Apr; 14(2):676-691. PubMed ID: 37201044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers.
    Kodama H; Masuishi T; Wakabayashi M; Nakata A; Kumanishi R; Nakazawa T; Ogata T; Matsubara Y; Honda K; Narita Y; Taniguchi H; Kadowaki S; Ando M; Muro K
    Clin Colorectal Cancer; 2023 Sep; 22(3):298-306. PubMed ID: 37270357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment.
    Zhang X; Zheng H; Cai C; Xu Y; Xie M; Wang Q; Jin X; Fu J
    PeerJ; 2023; 11():e15995. PubMed ID: 37719110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
    Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I
    Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Kang S; Kim SY; Hong YS; Kim TW; Choi KE; Kim MJ; Kim JE
    Sci Rep; 2023 Apr; 13(1):6735. PubMed ID: 37185297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis.
    Wu Q; Wang H; Zhang S; Zeng Y; Yang W; Pan W; Hong G; Gao W
    World J Surg Oncol; 2022 Aug; 20(1):258. PubMed ID: 35965307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
    Raga MG; Pérez IP; Veiga RC; Sosa MM; Aguilera MJS; Rodríguez PL; Bonastre MTT; Urtasun JA; Abad LP; Hernández IB
    Clin Transl Oncol; 2023 May; 25(5):1455-1462. PubMed ID: 36723787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer.
    Huang W; Zhang H; Tian Y; Cha Y; Xiong H; Yuan X
    J Clin Pharm Ther; 2022 Apr; 47(4):531-538. PubMed ID: 35218209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice.
    Dinu IM; Mihăilă M; Diculescu MM; Croitoru VM; Turcu-Stiolica A; Bogdan D; Miron MI; Lungulescu CV; Alexandrescu ST; Dumitrașcu T; Buică F; Luca IN; Lungulescu C; Negulescu MC; Gramaticu IM; Cazacu IM; Croitoru AE
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837551
    [No Abstract]   [Full Text] [Related]  

  • 15. Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital.
    Yuan M; Wang Z; Zhao Y; Feng T; Lv W; Zhong H
    Front Pharmacol; 2021; 12():632076. PubMed ID: 34122063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: A systematic review of randomized controlled trials.
    Chen L; Cao X; Li J; Liu C; Jiang T
    Medicine (Baltimore); 2022 Nov; 101(46):e31659. PubMed ID: 36401426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
    Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal Cancer.
    Yamamoto S; Fujii H; Murayama K; Iihara H; Watanabe D; Yamada Y; Kobayashi R; Kiyama S; Makiyama A; Urano K; Matsuhashi N; Suzuki A; Matsuura K
    Anticancer Res; 2023 Nov; 43(11):5099-5105. PubMed ID: 37909957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world first-line treatment of patients with BRAF
    Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D
    ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
    Zhou YW; Long YX; Liu X; Liu JY; Qiu M
    Future Oncol; 2022 Jul; 18(22):2453-2464. PubMed ID: 35712899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.